Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma
Preprint
Abstract
The profiles, specificity and dynamics of tumor-specific clonotypes that are associated with clinical response to adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) remain unclear. Using single-cell RNA/TCR-sequencing, we tracked TIL clonotypes from baseline tumors to ACT products and post-ACT blood and tumor samples in melanoma patients treated with TIL-ACT. Patients with clinical responses had baseline tumors enriched in tumor-reactive TILs, which were more effectively mobilized upon in vitro expansion, yielding products with higher numbers of tumor-specific CD8 + cells, which also preferentially infiltrated tumors post-ACT. Conversely, lack of clinical responses was associated with tumors devoid of tumor-reactive resident clonotypes, and with cell products mostly composed of blood-borne clonotypes mainly persisting in blood but not in tumors post-ACT. Upon expansion, tumor-specific TILs lost the specific signatures of states originally exhibited in tumors, including exhaustion, and in responders acquired an intermediate exhausted effector state after tumor engraftment, revealing important functional cell reinvigoration.Keywords
This publication has 69 references indexed in Scilit:
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patientsJournal of Clinical Investigation, 2016
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in TumorClinical Cancer Research, 2014
- Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma PatientsClinical Cancer Research, 2012
- TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patientsOncoImmunology, 2012
- Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancerBlood, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011
- Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune responseJournal of Experimental Medicine, 2009